Journal article icon

Journal article

A novel carcinoembryonic antigen t cell bispecific antibody (cea tcb) for the treatment of solid tumors

Abstract:

CEA TCB is a novel IgG-based T Cell Bispecific antibody for the treatment of CEA-expressing solid tumors currently in Phase 1 clinical trials (NCT02324257). Its format incorporates bivalent binding to CEA, a head-to-tail fusion of CEA and CD3e binding Fab domains and an engineered Fc region with completely abolished binding to FcγRs and C1q. The study provides novel mechanistic insights into the activity and mode of action of CEA TCB.CEA TCB activity was characterized on 110 cell lines in vit...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1158/1078-0432.CCR-15-1696

Authors


Colombetti, S More by this author
Weinzierl, T More by this author
Expand authors...
Publisher:
American Association for Cancer Research Publisher's website
Journal:
Clinical Cancer Research Journal website
Volume:
22
Issue:
13
Pages:
3286-3297
Publication date:
2016-02-09
DOI:
EISSN:
1078-0432
ISSN:
1078-0432
URN:
uuid:515dc835-2310-473f-9232-ffed858f0a79
Source identifiers:
606098
Local pid:
pubs:606098
Paper number:
13

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP